Sofinnova Partners

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Gradient Denervation Technologies develops an endovascular catheter-based medical device designed to treat pulmonary hypertension by reducing pulmonary vascular resistance and improving cardiovascular hemodynamics. Founded in 2019, the company is headquartered in Paris, France.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Founded in 1991, Sefas Innovation specializes in collaborative document composition and production software. Headquartered in Paris, France, with offices in the UK and US, it supports over 80 staff globally. Its Open Print software suite enables Fortune 500 companies across financial services, banking, insurance, utilities, telecoms, and public sectors to design, compose, and produce personalized B2C documents from multiple data sources.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.